To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

DIABETES DRUGS

TODAY'S HEADLINES

This diabetes drug is safer for the heart: Study

Find out which popular diabetes drug significantly reduced the risk of dying from heart attack and stroke, according to a new study. Read more

Drugmaker commits to "responsible pricing"

While drug manufacturers have come under fire for high prices—including Congressional hearings on the topic—one manufacturer is committing to "responsible" pricing. Read more

CONTINUING PHARMACY EDUCATION

The expanding role of direct oral anticoagulants in the management of thromboembolic disease

This month's CE activity is open for pharmacists and pharmacy technicians: "The expanding role of direct oral anticoagulants in the management of thromboembolic disease." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

National diabetes prevention program saves thousands

The average participant in a successful national diabetes prevention program lost 5% of their body weight, substantially reducing their risk of developing diabetes in the future. Here's how the program saved thousands in healthcare costs. Read more

April 22, 2016

National Managed Care Pharmacy Survey 2016

Your input is needed! Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, is seeking your opinion on the current state of pharmacy. Take the survey and you could win a $200 Visa gift card. Answer Now.

Related Articles

Major diabetes drug cuts heart attack risk

Top 7 new facts about drug spending

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us